Iyas Daghlas: DOACs Use, Genetic Reduction of Coagulation Factors and Risk of Cerebral Venous Thrombosis
Iyas Daghlas, Vascular Neurology Fellow and Stroke Researcher at the University of California, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Excited to share our new publication in Neurology: ‘Direct Oral Anticoagulant Protein Targets and Risk of Cerebral Venous Thrombosis: A Mendelian Randomization Study.’
Cerebral venous thrombosis (CVT) is a rare form of stroke treated with anticoagulation.
Despite widespread off-label direct oral anticoagulant (DOAC) use, no adequately powered RCT has demonstrated DOAC efficacy, and many patients continue to be treated with warfarin, which carries substantial major bleeding risk.
We addressed this evidence gap by examining effects of naturally randomized genetic variants perturbing the protein targets of established (F2+F10) and emerging (F11) DOACs.
See Table 1 for a cool demonstration of the natural allocation of covariates/confounders across genotypes, mimicking an RCT ‘Table 1.’
We found evidence that genetically reduced levels of thrombin, factor Xa, and factor XI are associated with reduced CVT risk – see forest plot!
What this means:
- FXI inhibitors (milvexian, asundexian, etc) are among the most actively investigated therapeutic targets in thrombosis today, with multiple Phase III trials underway. Our data provide the first human genetic evidence supporting repurposing potential for CVT, a new indication for this drug class.
- Human genetics supports efficacy for established DOAC protein targets (thrombin and factor Xa) in reducing CVT risk
- These data support the notion that, in general, therapeutics that are effective for venous thromboembolism will likely also work for CVT
Appreciate collaborators Marta Pérez Alcántara and Dipender Gill!”
Title: Direct Oral Anticoagulant Protein Targets and Risk of Cerebral Venous Thrombosis. A Mendelian Randomization Study
Authors: Iyas Daghlas, Marta Pérez Alcántara, Dipender Gill
Read the Full Article on Neurology
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 15, 2026, 09:10Shall I Bleed Less with Age? Just 2 Weeks Until the Webinar – EHC
-
Apr 15, 2026, 08:51Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS